FindMyKOL
Clinical trialNCT04751747Active, not recruitingInterventional

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

NCT04751747 is an interventional trial sponsored by Rutgers, The State University of New Jersey. As of 21 Nov 2026, it is active and no longer recruiting. It studies Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma and 11 more conditions. The registry lists an enrollment of 34 participants at 2 sites in 1 country. The registry lists a start date of 11 Feb 2021 and a primary completion date of 31 Dec 2026. One of its registered investigators has a FindMyKOL profile.

SponsorRutgers, The State University of New JerseyEnrollment34Locally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8+7 more conditions
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04751747
FieldValue
Registry IDNCT04751747
StatusActive not recruiting
Study typeInterventional trial
Lead sponsorRutgers, The State University of New Jersey
Enrollment34
Registered sites2
Countries1
ConditionsLocally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8 and 7 more conditions
Start11 Feb 2021
Primary completion31 Dec 2026
Study completion31 Dec 2027
Last update posted11 Jun 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the effect of adaptive radiation planning in reducing side effects associated with radiation treatment and immunotherapy in patients with stage II-IV non-small cell lung cancer. Prior to radiation, patients undergo simulation, where they are positioned on the treatment table in a manner that can be reproduced each time they receive treatment in order to reach the tumor exactly at the same spot each time. However, a patient's tumor may shrink as they receive radiation, exposing healthy tissue to radiation as well. Adaptive radiation planning involves re-designing a treatment plan at set intervals. The purpose of this study is to see whether establishing set time points through adaptive radiation planning, regardless of whether the doctor notices a significant decrease in tumor size, will reduce some of the side effects associated with radiation treatment and immunotherapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New Jersey, United States2 sites
  • Rwjbarnabas Health - Robert Wood Johnson University Hospital

    New Brunswick

  • Rutgers Cancer Institute of New Jersey

    New Brunswick

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew Jersey: 2 sitesNJ2ConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT04751747

Each answer restates registry values shown on this page.

What is NCT04751747?

NCT04751747 is an interventional trial sponsored by Rutgers, The State University of New Jersey. It studies Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma and 11 more conditions.

Is NCT04751747 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04751747?

The registry names Salma K Jabbour, MD (principal investigator, Rutgers Cancer Institute of New Jersey) as the overall official.

Where does NCT04751747 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

When is NCT04751747 expected to complete?

The registry lists a primary completion date of 31 Dec 2026 and a study completion date of 31 Dec 2027. The sponsor last updated the record on 11 Jun 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.